Is the Universe’s Expansion Slowing Down?

Tycho supernova remnant

NASA/CXC/RIKEN & GSFC/T. Sato et al. DSS

Many believe that our universe is expanding at an accelerating rate. However, a team of South Korean researchers has posited a different perspective, leading other scientists to raise significant concerns about their claims.

Since the Big Bang 13.8 billion years ago, the universe has been in a state of expansion. Evidence from distant dying stars known as type 1a supernovae supports the idea that this expansion is accelerating. The theory behind this acceleration is often attributed to a mysterious force dubbed dark energy, which earned the Nobel Prize in Physics in 2011.

Lee Young Wook and colleagues at Yonsei University argue against this widely accepted explanation. Type 1a supernovae occur when the remnants of a Sun-like star, termed a white dwarf, explode in a binary star system. These supernovae are classified as “standard candles,” as they provide consistent measurements for cosmic distances due to their uniform brightness.

However, Li and his team assert that based on an analysis of 300 host galaxies, the brightness of these supernovae significantly varies with the age of the star. They propose that this “age bias” leads distant supernovae to appear dimmer due to the universe’s accelerating expansion, suggesting that accounting for this could negate the perceived acceleration of the universe.

Professor Lee indicates that their findings imply the universe’s expansion began to decelerate 1.5 billion years ago and could ultimately reverse—an event astronomers describe as a “big crunch,” potentially culminating in an inverted big bang. “Previously, the notion of a major crisis was dismissed, but now it has become a possibility,” he remarked.

Adam Rees, a researcher at the Space Telescope Science Institute in the US and a 2011 Nobel laureate, refutes these claims, noting that earlier investigations from the same team in 2020 contradicted their current argument. He remarked, “A new study from the same group reiterates this viewpoint with minimal changes,” pointing out the difficulty in measuring stellar ages of type 1a supernovae across vast distances. He emphasized that Li’s team used average stellar ages derived from the host galaxy, which he believes weakens their theory due to uncertainties in stellar formation.

Researchers have acknowledged existing questions regarding the influence of stellar age on the brightness of Type 1A supernovae throughout the universe. Mark Sullivan from the University of Southampton expressed skepticism about the notion of a slowing universe, citing ongoing discussions about dark energy measurements.

Future observations from the Vera C. Rubin Observatory in Chile are anticipated to greatly enhance our catalog of type 1a supernovae, expanding from several thousand to tens of thousands. This influx of data could enable researchers to chart the universe’s expansion history far back in time, potentially discrediting the claims made by Lee’s team.

Nevertheless, the precise nature of dark energy remains elusive. Recent findings from the Dark Energy Spectroscopy Instrument (DESI) hinted at the possibility that dark energy is not a constant force and may evolve over time. While this does not imply the universe is currently decelerating, it does suggest variations in the expansion rate over cosmic history.

“Current evidence points towards dark energy being more complex than a cosmological constant—suggesting it may be some dynamic entity,” states Ed Macaulay at Queen Mary University of London. “This raises intriguing questions about its true nature.”

topic:

Source: www.newscientist.com

Ibogaine: A Psychedelic Drug That May Alleviate PTSD by Slowing Brain Waves

Ibogain, a psychedelic substance, is derived from the roots of the Iboga plant

Farmer Dods / Alamy

The psychedelic substance ibogaine has been shown to slow brain wave activity in individuals with traumatic brain injuries, potentially accounting for its effectiveness in treating symptoms of post-traumatic stress disorder (PTSD).

A study conducted last year revealed that ibogaine, sourced from the African Iboga plant, significantly enhanced the overall mental and physical well-being of military veterans suffering from traumatic brain injuries. Yet, the precise mechanisms behind these effects were previously unknown.

To investigate further, Jennifer Lismore from Stanford University and her team examined brain imaging of 30 individuals involved in the initial study. During a 5-day treatment session at a facility in Mexico, participants received a dosage of 12 milligrams of ibogaine per kilogram of body weight and participated in supportive activities like yoga, meditation, and therapy.

As part of the study, the researchers collected EEG data that recorded participants’ brain electrical activity. These scans were taken 2-3 days prior to and 3.5 days following the ibogaine treatment.

By comparing the EEG findings, Lismore and her team observed an overall deceleration in brain wave activity post-treatment, particularly in the gamma waves—the fastest brain waves—which exhibited nearly a 16% reduction in strength in the occipital region after ibogaine therapy. While gamma wave intensity saw a slight rebound after one month, levels remained significantly below those recorded prior to treatment.

Additionally, the intensity of slow theta waves rose by approximately 17% in the back of the brain and 13% at the front 3.5 days post-treatment. However, this increase lost its significance after one month.

Lismore suggests that the observed reduction in brain wave activity may clarify why ibogaine is effective for alleviating PTSD symptoms in many patients. “The deceleration of brain function has allowed patients, particularly those experiencing hyperawareness and sensitivity associated with PTSD, to find relief,” she noted. “One way to understand this slowing process is as a mitigation of the heightened distress often seen in PTSD cases.”

The temporary spike in slow theta waves could also indicate that ibogaine promotes neuroplasticity—the brain’s ability to adapt and rewire itself. Previous studies in animals have associated theta wave activity with brain adaptability, Lismore explains. By inducing a short-term increase in theta wave presence, ibogaine may create conditions conducive to improving mental health.

“Ibogaine essentially addresses the chaotic, restless nature of the brain, facilitating a sort of normalization,” remarked Conor Murray from the University of California, Los Angeles. “Ultimately, it instills a sense of security for participants, reassuring the brain.”

However, he cautions that these findings don’t fully reveal the mechanisms through which ibogaine effects these brain changes.

Another challenge is the absence of control measures, complicating the assessment of the influence from other treatment components, points out Lismore. Nonetheless, she asserts that these insights represent “a significant first step toward understanding why this treatment is so impactful.”

Topics:

Source: www.newscientist.com

Researchers Explore the Potential of Ambroxol in Slowing Parkinson’s-Related Dementia

Ambroxol, a cough medication, is authorized in Europe for treating respiratory issues and boasts a long history of safety, including its use in high doses and during pregnancy, but it has not been approved in the US or Canada.

Ball and stick model of ambroxol molecules. Image credit: Marina Vladivostok/Chemspider.

Dementia in individuals with Parkinson’s disease can lead to memory loss, confusion, hallucinations, and mood changes.

About half of those diagnosed with Parkinson’s disease will develop dementia within a decade, significantly affecting patients, families, and healthcare systems.

“Our objective was to alter the trajectory of Parkinson’s dementia,” stated Dr. Steven Pasternack, a cognitive neurologist at the Parkwood Institute, St. Joseph’s Healthcare London, and the Robert Institute.

“This preliminary trial offers hope and establishes a robust basis for further research.”

The 12-month clinical trial involved 55 participants suffering from dementia related to Parkinson’s disease.

One group received daily ambroxol, while the other was administered a placebo.

They assessed memory, psychiatric symptoms, and GFAP, markers linked to brain damage in the blood.

The research team noted that ambroxol is safe, well-tolerated, and effectively penetrated the brain.

The placebo group exhibited worsening psychiatric symptoms, while those taking ambroxol remained stable.

Participants with GBA1 genetic mutations showed enhanced cognitive performance with ambroxol treatment.

GFAP levels rose in the placebo group but stayed stable in those using ambroxol, indicating potential brain protection.

“Existing treatments for Parkinson’s disease and dementia focus on symptoms without addressing the root cause,” Dr. Pasternack explained.

“These findings imply that brain function at genetic risk may be preserved, marking a promising new treatment avenue that is currently limited.”

Ambroxol aids an essential enzyme known as Glucocerebrosidase (GCase) linked to the GBA1 gene.

In patients with Parkinson’s disease, GCase levels are frequently reduced. If this enzyme malfunctions, waste builds up in brain cells, resulting in damage.

“This research is crucial as dementia in Parkinson’s disease significantly impacts patients and their families,” remarked Dr. Pasternack.

“If a medication like ambroxol proves beneficial, it can offer true hope and enhance quality of life.”

The results will be published in the journal Jama Neurology.

____

Carolina La Silveilla et al. Ambroxol as a treatment for Parkinson’s disease dementia: a randomized clinical trial. Jama Neurology Published online on June 30th, 2025. doi:10.1001/jamaneurol.2025.1687

Source: www.sci.news

Research indicates that intermittent fasting may have a major impact on slowing down hair growth

Intermittent fasting can be effective for weight loss, but it can also have negative effects on hair growth, as shown in a recent mouse experiment conducted by researchers at Westlake University in China. The study found that mice undergoing intermittent fasting experienced improved metabolic health but showed delayed hair regrowth. This link between restrictive eating and hair regrowth was also observed in a study published in Cell.

While similar effects may occur in humans, they are typically less severe due to differences in metabolic rate and hair growth patterns. Nevertheless, it is important to be aware of the potential unintended consequences of intermittent fasting, as highlighted by senior author and stem cell biologist Dr. Bing Zhang.

Further research is needed to fully understand the effects of fasting on hair growth, as current studies have primarily focused on its benefits for blood, muscle tissue supply, and metabolism. The research team at Westlake University conducted experiments on mice to explore the impact of intermittent fasting on hair regrowth, with findings suggesting that prolonged fasting stresses hair follicle stem cells, leading to delayed hair growth.

A small clinical trial involving 49 healthy young individuals showed that time-restricted eating with 18 hours of daily fasting reduced hair growth by an average of 18 percent. However, the researchers caution that the study’s small sample size and short duration may yield different results in larger-scale studies.

Future research will investigate how fasting affects other types of stem cells in the body and its implications for wound healing speed. Despite the potential drawbacks, intermittent fasting remains a popular and beneficial practice for many individuals.

Source: www.sciencefocus.com

Nvidia Continues Impressive Growth as AI Chip Leader Shows no Signs of Slowing Down

Nvidia, the AI chip maker that is the world's most valuable company and the driving force behind the artificial intelligence boom, delighted investors on Wednesday with new quarterly results.

The company's corporate value soared by $2.2 trillion this year to $3.6 trillion on the back of nearly doubling chip sales, but sales fell to $35.08 billion, compared to expectations of $33.15 billion. It was announced that it was worth $1,000,000. Profits more than doubled compared to the same period last year. Sales increased by 94% compared to the same period last year. The company predicted a 70% increase in revenue for the next quarter.

Analysts had expected NVIDIA to report earnings of $0.75 per share. The company reported $0.81. Nvidia stock fell about 5% in extended trading following the announcement, but quickly recovered its losses and maintained a similar price. The previous New York closing price was $145.89.

Nvidia CEO Jensen Huang said in a press release last week that he expects the computing power driving advances in generative AI to increase “a million times” over the next decade.

Huang said on the earnings call that the global adoption of Nvidia technology is causing a platform shift from coding to machine learning, and traditional data centers are being re-architected for machine learning to produce AI. said.

“Generative AI is not just a new software feature, it’s a new industry with AI factories producing digital intelligence, a new industrial revolution with the potential to create a multi-trillion dollar AI industry,” he said. .

“AI is transforming every industry, business, and country,” Huang added. “Creating an omniverse of synthetically generated data…the era of robotics is here.”

A surge in demand for Nvidia's Blackwell GPU chips appears to have eased fears that the company would be hit by a backlash in demand from tech giants, which are spending billions of dollars on AI processing and data centers. .

Nvidia stock has rebounded from its summer slump and is up 45% from its August lows. Semiconductor stocks are up nearly 200% this year, more than 1,100% over the past two years, and hit a record high after the election.

However, many of NVIDIA's chipmakers are struggling to compete with the advantages of AI, which is holding the industry back.

Before the results were released, Wedbush analyst Dan Ives said he expected more “drop-the-mic performance” from Nvidia, adding that “it's expected to generate more than $1 trillion in the next few years.” “This is the only game in the city where AI capital investment is planned.” Nvidia's GPUs will bring new oil and gold to this world. ”

The world's largest technology companies have increased their spending on AI by billions of dollars in recent quarters, with Nvidia positioned as a major beneficiary.

Nvidia is seen by many as a bellwether for the technology sector and artificial intelligence demand that helped propel Wall Street to multiple record highs this year.

Skip past newsletter promotions

But the escalation of the Russia-Ukraine war, the threat of global tariff hikes by the incoming Donald Trump administration and the possibility that the US Federal Reserve will not lower US interest rates are also spooking markets.

Other analysts echoed Ives' assessment that demand for Nvidia's new Blackwell chips could push Nvidia's sales and market capitalization to new heights. Charu Chanana, Saxo's chief investment strategist, said signs of “extraordinary demand” for new chips, including record sales forecasts and reports of sold-out inventory next year, are strong indicators that Nvidia's strong performance will continue. I wrote that.

But Chanana cautioned that “any signs of production delays or lack of demand could put pressure on the stock given valuation growth.”

Earlier this week, report Chipmakers say their latest graphics chips are having overheating problems with servers. www.theguardian.com

Possible Future Solutions for Slowing, Stopping, or Eradicating Alzheimer’s Disease

Alzheimer’s disease is, understandably, one of the most feared diseases of old age. It robs people of their memories, places a tremendous strain on caregivers, and imposes a huge economic burden on both individuals and society. Tens of millions of people have already been diagnosed with Alzheimer’s, and if predictions are correct, that number will more than double by 2050.

Until recently, it seemed there was no hope of averting this catastrophe, but rapid advances in medical science have made it realistic prospects that Alzheimer’s may be treatable and eventually eradicated (see “A new kind of vaccine could lead to Alzheimer’s eradication”).

The first of a new class of drugs is already creating buzz, but not necessarily for the right reasons. Last week, the UK’s Medicines and Healthcare products Regulatory Agency approved the drug, called lecanemab. But NICE, the body that advises on whether new treatments are cost-effective, has made a provisional decision that taxpayers will not fund the drug in England. No decision has yet been made in the rest of the UK.

This is obviously a tough pill to swallow for Alzheimer’s patients and their families. But in the grand scheme of things, this is good news. Lecanemab is not a particularly effective drug. Its effects are modest, it has serious side effects, and it is expensive. But it does show that the causes of Alzheimer’s are now understood and treatable. This is further reinforced by the fact that the drug is also approved in the United States and Japan, but the European Medicines Agency has refused to approve it.

So the way is almost paved for the next wave of drugs to target the causes of Alzheimer’s, which could be ready around 2030. These are vaccines, not in the traditional sense of conferring immunity against an infection, but they work in essentially the same way, by stimulating an immune response against the misfolded proteins that cause the symptoms of Alzheimer’s. The first vaccines will be therapeutic, slowing or stopping the progression of Alzheimer’s, but the next generation will be preventative, preventing the onset of Alzheimer’s. Eventually, the only memory that will fade will be Alzheimer’s itself.

Source: www.newscientist.com

Investors spooked by slowing growth cause Nvidia shares to fall

Shares in the chip designer Nvidia have fallen after investors were spooked by signs of slowing growth and production issues, despite the artificial intelligence company posting a 122% rise in second-quarter revenues compared with the same period last year.

The Silicon Valley company’s revenues for the period more than doubled to $30bn (£23bn), beating average analyst estimates of $28.7bn. However, investors were concerned about signs of a slowdown in growth, in particular around its next-generation AI chips, code-named Blackwell.

The stock fell as much as 7% in pre-market trading, before paring back losses to a 3% fall. The chipmaker is the third most valuable company in the world, with a market value of $3.1tn.

Nvidia said the delivery of its Blackwell chips – which comprises 208bn transistors that carry out calculations to train its large language model – would be delayed by several months from January. Its chief executive, Jensen Huang, has previously said that Blackwell would generate “a lot of revenue” for the business this year.

Simon French, the chief economist and head of research at the investment bank Panmure Liberum told the BBC: “There were just some signs around the edges in numbers that that rate of growth was trying to slow.

“Their current AI chip ‘hopper’ is selling well, but the next one, the next generation Blackwell, has faced some production delays, and that perhaps is one of the reasons why Wall Street, after hours, sold off the stock.”

Speaking to investors and journalists overnight, Nvidia bosses did not detail the extent of the delay for Blackwell deliveries but said manufacturing issues had been addressed by TSMC, the Taiwanese semiconductor firm that builds the US company’s most advanced chips. They added that early samples were now shipping to a small group of customers

The drop in Nvidia’s share price dragged on US markets, in particular the S&P 500 index. Nvidia makes up about 6% of the total value of the index and has helped drive its gains this year, after rising more than 160% over the past 12 months.

Matt Britzman, an analyst at the investment platform Hargreaves Lansdown, said Nvidia was facing the major challenge of how to match the hype. “It’s less about just beating estimates now, markets expect them to be shattered and it’s the scale of the beat that looks to have disappointed a touch.”

While many investors have bought into the theoretical impact of artificial intelligence and claims that it could transform nearly every global industry, French noted that the practical use cases “haven’t yet been proven”.

skip past newsletter promotion

“Such are the lofty expectations for this stock, not just as a single company, but its broader economic impact,” he said. “If you’re going to raise expectations that high, then you’ve got to keep growing at spectacular rates .”

However, Britzman cautioned against reading too much into the market reaction, given that investors tended to “overstate” the importance of one set of quarterly results, particularly in the “grand scheme of AI” prospects. Instead, he said companies such as Microsoft and Tesla, and the Facebook and Instagram owner, Meta, were working on a “multi-year, even multi-decade, time frame and investors would be wise to adopt a similar mentality”.

He added: “The question of return on investment, that many AI bears fall back on, simply isn’t the main consideration for Nvidia’s biggest customers at this stage. Like many before, this cycle won’t be a straight line, but while the ‘build it and they will come’ approach continues, it plays right into Nvidia’s hands.”

Source: www.theguardian.com

Slowing Alzheimer’s Disease Progression: How Light and Sound Can Remove Toxins from the Brain

Cross-section of a mouse brain highlighting neurons that appear to release molecules that increase toxin clearance

Tsai Laboratory/MIT Picower Laboratory

A new explanation has emerged for why an experimental treatment for Alzheimer’s disease that involves flickering sounds and lights may help slow cognitive decline. This frequency appears to strengthen the brain’s waste processing network, helping to remove beta-amyloid and other toxic proteins that contribute to memory and concentration issues.

“Once we understand the mechanism, we can probably understand how to further optimize this whole concept and improve its effectiveness,” he says. Cai Li Hui at Massachusetts Institute of Technology.

The treatment involves exposure to light that flashes at a frequency of 40 times per second, or 40 hertz, and to a bass sound, also at 40 hertz. Typically, stimulation is given for one hour per day.

The key to this new approach is that large networks of brain cells naturally fire in sync with each other at different frequencies, known as brain waves. Brain waves around 40 Hz are common when people are concentrating and forming or accessing memories.

In 2016, Tsai’s team wondered if 40Hz stimulation could enhance cognitive performance in Alzheimer’s patients, since visual or auditory stimulation at a certain frequency is known to enhance brain waves at that same frequency. I decided to investigate.

Their group and other researchers have shown that this reduces amyloid accumulation in mice with Alzheimer’s disease and has cognitive benefits. Small trial in people with this condition, an even larger trial is underway. However, it is unclear how this treatment works, and another idea is that it boosts the function of immune cells in the brain.

Well, the special light and sound appears to work by enhancing the function of the brain’s drainage system, also known as the glymphatic system.

In the latest study, Tsai’s team conducted a series of experiments to study the mechanism of treatment in mice that were genetically modified to have amyloid buildup that normally occurs with age and to have worse memory than typical mice. carried out.

As expected, when the animals were exposed to light and sound, the amount of amyloid decreased. The new findings were that during treatment, the amount of cerebrospinal fluid entering the brain increased, and the amount of waste fluid leaving the brain through the glymphatic vessels increased.

This appears to occur because nearby blood vessels pulsate more, which may help glymph fluid flow through the blood vessels, allowing more water to flow into the glymph system.

The research team also found that the activity of a particular type of brain cell known as an interneuron appears to cause an increase in glymph flow by releasing a molecule called vasoactive intestinal peptide. When the research team chemically blocked the production of this molecule, the treatment no longer accelerated amyloid clearance.

Miken Nedergaard A professor at the University of Rochester in New York who helped discover the glymphatic system says the discovery is consistent with what we already know about it. “The brain, blood, and cerebrospinal fluid are all contained within the skull. When the blood volume expands, the brain tissue cannot be compressed, so the cerebrospinal fluid volume must also move.”

In the accompanying article natural medicineDr. Nedergaard says that a better understanding of the mechanisms of toxin removal in the brain “could be the key to unlocking that.” [their] Treatment Possibilities.”

topic:

Source: www.newscientist.com

Slowing Aging and Preventing Dementia Through Restoration of Brain Mitochondria

Protein plaques in the brain may be caused by mitochondrial dysfunction

Sebastian Kauritzky/Alamy

If you own a car, you’ve probably noticed that your engine becomes less efficient over time. The farther you drive, the more fuel it takes to cover the same distance. Eventually, you’ll end up with so little power that you need a physical push to climb a gentle hill.

It is now becoming clear that much the same holds true for the human brain. Microscopic structures called mitochondria, found in all brain cells, are literally the engines of our thoughts and emotions. As we age, we find it increasingly difficult to generate enough energy to power mental activity. Worse, just like an old car leaves behind a cloud of smoke, the power source of our cells begins to produce unnecessary waste products that slowly pollute our brains. This means that mitochondrial dysfunction may underlie some of the most serious brain diseases, including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and motor neuron disease.

According to this “grand unified theory” of neurodegeneration, recharging neurons through restoration of their power plants can prolong healthy brain function. This idea has already inspired some exciting new treatments for age-related brain diseases, with multiple drug candidates under investigation. Some researchers are exploring the possibility of transplanting healthy mitochondria into damaged, aging brains to reactivate them. “If you keep replacing the parts in your car, it can last forever,” he says. claudio soto, a neurologist at the University of Texas Health Science Center at Houston. “So what happens if we try to run this…

Source: www.newscientist.com